

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 September 2020 (03.09.2020)



(10) International Publication Number
WO 2020/172698 A1

(51) International Patent Classification:

A61K 31/7028 (2006.01) **A61P 39/00** (2006.01)
A61P 7/00 (2006.01) **A61P 43/00** (2006.01)
A61P 31/00 (2006.01)

(21) International Application Number:

PCT/AU2019/050156

(22) International Filing Date:

25 February 2019 (25.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicants: **THE AUSTRALIAN NATIONAL UNIVERSITY** [AU/AU]; Director of Technology Transfer, X-005 Childers Street, Level 6, Acton, Australian Capital Territory 2601 (AU). **GRIFFITH UNIVERSITY** [AU/AU]; 170 Kessels Road, Nathan, Queensland 4111 (AU).

(72) Inventors: **PARISH, Christopher**; Unit 8, 57 Eyre Street, Kingston, Australian Capital Territory 2604 (AU). **O'MEARA, Connor**; 611/67 Watt Street, Newcastle, New South Wales 2300 (AU). **COUPLAND, Lucy**; 5 Wurth Place, Chifley, Australian Capital Territory 2606 (AU). **QUAH, Benjamin Ju Chye**; 9 Goolara Place, Jerrabomberra, New South Wales 2619 (AU). **KORDBACHEH, Farzaneh**; 74/39 Benjamin Way, Belconnen, Australian Capital Territory 2617 (AU). **BEZOS, Anna**; 13 Carnegie Crescent, Narrabundah, Australian Capital Territory 2604 (AU). **BROWNE, Anna**; c/- The Australian National University, Acton, Australian Capital Territory 2601 (AU). **STEPHENS, Ross**; 18 McKail Cr, Stirling, Australian Capital Territory 2611 (AU). **TREDWELL, Gregory David**; 6/219A Northbourne Avenue, Turner, Australian Capital Territory 2612 (AU). **PHILIP, Lee Andrew**; 3 Granville Close, Greenleigh, New South Wales 2620 (AU). **KNOX, Karen**; 89/160 Bagnall Street, Ellen Grove, Queensland 4078 (AU). **VON ITZSTEIN, Laurence Mark**; 10 Blue Gum Crt, Gilston, Queensland 4211 (AU). **CHANG, Chih-Wei**; 26 Greenleaf Street, Upper Comma, Queensland 4209 (AU). **BRÜSTLE, Anne**; C/- The John Curtin School of Medical Research, Acton, Australian Capital Territory 2601 (AU). **DAVIS, David Anak Simon**; Unit 73, 8 Ver-

yard Lane, Belconnen, Australian Capital Territory 2617 (AU).

(74) Agent: **WRAYS PTY LTD**; Level 7, 863 Hay Street, Perth, Western Australia 6000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS FOR TREATING AND PREVENTING NET ASSOCIATED COMPLICATIONS

(57) Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of β -O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.



WO 2020/172698 A1